Acceptability, Feasibility, and Effectiveness of Caregiver-assisted HIV Self-testing Among Children Using an Oral Mucosal Test in Uganda and Zambia: a Prospective Interventional Study.

Details

• Alternative Title:
  The Lancet. HIV, 2025, v. 12, no. 5: Acceptability, Feasibility, and Effectiveness of Caregiver-assisted HIV Self-testing Among Children Using an Oral Mucosal Test in Uganda and Zambia: a Prospective Interventional Study.
• Journal Article:
  The Lancet. HIV
• Personal Author:
  Gross, Jessica ; Tumwesigye, Nazarius M ; Mutembo, Simon ; Moyo, Nkumbula ; Mukose, Aggrey ; Chilyabanyama, Obvious ; Matoba, Japhet ; Parris, KaeAnne ; Lee, Brianna ; Churchill, Taralyn ; Williamson, Dhelia ; Pals, Sherri ; Biribawa, Claire ; Kagaayi, Joseph ; Ndubani, Phillimon ; Okello, Francis ; Zyambo, Zude ; Taasi, Geoffrey ; Magongo, Eleanor N ; Munthali, Gloria ; Mwiya, Mwiya ; Nazziwa, Esther ; Awor, Anna C ; Itoh, Megumi ; Boyd, Adetinuke Mary ; Macleod, David ; Rivadeneira, Emilia ; Oliver, Daniel ; Ferrand, Rashida A ; Stecker, Carl
• Description:
  During the COVID-19 pandemic, the US President's Emergency Plan for AIDS Relief supported oral caregiver-assisted HIV self-testing (CG-HIVST) to address the gap in HIV diagnosis of children. We aimed to investigate caregiver uptake, results return, acceptability, and potential social harms of CG-HIVST.
  
  This prospective, interventional, study was done at 32 health facilities in Uganda and 15 health facilities in Zambia. Caregivers aged 18 years and older (plus emancipated minors aged 15-17 years in Uganda) living with HIV who were currently accessing HIV care and considered index cases, with no positive responses to an intimate partner violence screen, and with one or more children aged 18 months to 14 years with unknown HIV status were eligible to participate. Eligible caregivers were offered oral HIVST kits to screen their children and primary outcomes were described by caregiver and child characteristics. Following HIVST kit administration, caregivers were surveyed using a standardised questionnaire to document their perceptions, adverse events, and social harm. Primary outcomes were the uptake of HIVST and the number and proportion of returned screening test results, reactive results, reactive screens with confirmatory HIV testing, confirmatory testing with a positive result, and children who were confirmed HIV-positive who were linked to treatment. This study was registered with ClinicalTrials.gov, NCT04774666 and NCT04754386, and is completed.
  
  From Feb 1 to Oct 31, 2021, 12 998 interested caregivers were screened for eligibility, 4023 of whom were eligible. 3903 (97·0%) accepted HIVST kits to screen their child for HIV (1609 41·2% in Zambia and 2294 58·8% in Uganda). Among caregivers, 3094 (79·3%) of 3903 were female, and 809 (20·7%) were male. 7601 children were enrolled (3779 49·7% were female and 3822 50·3% were male). 4766 (97·9%) of 4866 test results were returned in Uganda and 2647 (96·8%) of 2735 in Zambia. 119 (1·6%) of 7413 children had reactive HIVST results, requiring confirmatory testing. Of 116 children with confirmatory testing, 43 were confirmed HIV-positive (HIV prevalence 0·7% n=32 in Uganda and 0·4% n=11 in Zambia) and 100% were linked to antiretroviral therapy. Adverse events were rare (11 0·4% of 2720) and minor, and there were no reports of social harm or violence. Caregivers surveyed reported the HIVST kit was easy to use (2637 97·0% of 2718), they would use it again (2650 99·1% of 2674), and they would recommend it to other parents (2615 97·8% of 2674).
  
  Our findings suggest that oral CG-HIVST is acceptable, feasible, and safe, with no reports of social harm, and has the potential to expand access to HIV testing for children while reducing the service delivery burden on health facilities.
  
  US President's Emergency Plan for AIDS Relief and Wellcome Trust.
• Content Notes:
  Author manuscript
• Subjects:
  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Caregivers
  More +
• Source:
  The Lancet. HIV, 2025, v. 12, no. 5
• DOI:
  https://doi.org/10.1016/S2352-3018(25)00005-0
• ISSN:
  2405-4704 ; 2352-3018
• Pubmed ID:
  40316402
• Pubmed Central ID:
  PMC12993861
• Document Type:
  Text
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Genre:
  Journal Article
• Place as Subject:
  Uganda ; Zambia
• Pages in Document:
  e325-e337 (24 pdf pages)
• Volume:
  12
• Issue:
  5
• Download URL:
  https://stacks.cdc.gov/view/cdc/261440/cdc_261440_DS1.pdf
• File Type:
  [PDF - 814.72 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:48d415d5257910e327a9ce93bdf99d9be82f5ee989d9b0b0ae67c45d04eb415d7863b362839d39e2d0f5151d27e7ec82de8b1915d770c6edd024faa7ac333c0f